Strategic roadmap for delivery of clinical trials in rare childhood central nervous system (CNS) tumours: a multi-stakeholder consensus.
A multidisciplinary UK workshop developed a strategic roadmap for trials in four rare pediatric CNS tumor groups, prioritizing coordinated data collection, international collaboration, and efficient designs such as platform, adaptive, Bayesian, and external-control approaches.
Open original publication →What the AI sees
A multidisciplinary UK workshop developed a strategic roadmap for trials in four rare pediatric CNS tumor groups, prioritizing coordinated data collection, international collaboration, and efficient designs such as platform, adaptive, Bayesian, and external-control approaches.
Research significance
The record provides consensus-based support for trial-infrastructure and design strategies rather than evidence for a specific therapy; it is reasonable to infer that implementing these strategies could accelerate evaluation of treatments in very small pediatric CNS tumor populations, but no therapeutic efficacy, safety, or outcome improvement is demonstrated.
Source abstract
Rare paediatric central nervous system (CNS) tumours comprise a biologically-heterogeneous group of low-incidence diseases that present significant challenges to both therapeutic development and clinical research, limiting the availability of high-quality evidence to guide clinical care. The UK3CR Children's Cancer Research Group (CRG) CNS Tumours Subgroup convened a multidisciplinary workshop to identify research priorities and establish a strategic framework for advancing clinical trials in this setting. Four high-priority tumour groups-craniopharyngioma, choroid plexus carcinoma (CPC), very high-risk medulloblastoma (VHR-MB), and rare embryonal and sarcomatous tumours (REST), including embryonal tumour with multilayered rosettes (ETMR)-were evaluated. Key outcomes included the feasibility of a UK-led craniopharyngioma trial, the need for enhanced national CPC data collection, and support for European early-phase platform trials in VHR-MB. REST highlighted transnational regulatory complexity requiring coordinated registries and parallel trial models. Cross-cutting barriers included regulatory discordance, contracting delays, fragmented funding, pharmacovigilance differences, data-sharing constraints, and interoperable infrastructures. The workshop emphasised innovative methodologies, including Bayesian/adaptive designs, platform trials, and external control arms, to maximise efficiency in small populations, alongside strengthened patient involvement and international collaboration. Collectively, these findings define a collaborative and internationally-aligned strategic roadmap to accelerate clinical research and improve outcomes in rare paediatric CNS tumours.